It's exciting to think we're on the brink of a genomic revolution in health care. But just because new technology becomes available, it doesn't mean it should automatically be publicly funded.
In 2030, there is a boom in precision medicine, where diseases – from cancer to dementia – are defined and targeted more specifically with a focus on their molecular makeup.
DNA marketplaces powered by the blockchain and new cryptocurrency tokens promise to let you profit from your own genome.
The rapid growth of genetic testing and data-gathering could revolutionize health and medicine if governments work to protect people against privacy and societal risks.
New research offers insight into a thorny issue.
If you could take a test that would reveal the diseases you and your family might be more likely to get, would you want to do it?
Canadian insurance companies argue that a new law denying them access to genetic test results will raise the cost of insurance for everyone. That's doubtful.
Life insurance applicants must disclose genetic test results if required by the insurer. While other countries have protected consumers from this, there is no such regulation in Australia.
Most people will be much better off putting the money spent on a genetic test towards a gym membership, or a pair of trainers.
Most of us will be carriers of recessive genes that cause disease. If our partner carries the same gene we could pass it on to our kids. Testing exists, but what are the pros and cons?
A test of all your genes for disease risk is not yet the precision diagnostic and treatment tool we hope it will one day be.
Genetic testing is revealing important information about disease risks, and consumers can now pay for a test to know their risk. They might be better off if their doctors considered these risks, too.
Testing some genes for Alzheimer's disease, coeliac disease and folate conversion does not lead to improved health outcomes, and may create anxiety or false hope amongst patients.
Dozens of factors are at play.
Why can we choose some things and not others?
The rise of personalised medicine, which is mainly based on genetic testing, needs adequate regulation so privacy rights aren't breached. That's only one of several issues that must be considered.
Next-generation genomic research depends on study participants sharing their biological materials with scientists. But concerns over how that information is protected may hold some people back.
When you enter a Chemmart pharmacy, it's hard to miss the posters and brochures promoting its “revolutionary myDNA test”.
The most important lesson? Always read the small print.
Why does the same medication, at the same dose, work well for some people, but not for others? The answer is in our genes.